International healthcare investment group OrbiMed has raised around $4.3 billion in committed financing for distribution across three new private funds that will be used t
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.